Table 1 Demographic, clinical, and CPB data of trial groups
ModHT Group (n = 10) | MiHT Group (n = 10) | p Value | |
|---|---|---|---|
Age (y) | 70.6 ± 9.7 | 67.7 ± 12.3 | 0.565 |
Female, n (%) | 4 (40%) | 4 (40%) | 1.000 |
Hypertension, n (%) | 6 (60%) | 6 (60%) | 1.000 |
Smoking history, n (%) | 4 (40% | 2 (20%) | 0.626 |
Diabetes, n (%) | 2 (20%) | 1 (10%) | 1.000 |
Hyperlipidemia, n (%) | 4 (40%) | 2 (20%) | 0.626 |
Atrial fibrillation, n (%) | 2 (20%) | 4 (40%) | 0.626 |
LVEF (%) | 62.2 ± 17.1 | 57.8 ± 17.8 | 0.580 |
CPB time (min) | 85.2 ± 11.3 | 87.5 ± 21.1 | 0.765 |
Aortic crossclamping time (min) | 59.2 ± 7.8 | 59.0 ± 16.6 | 0.973 |
Minimal core CPB temperature (nasopharyngeal) (°C) | 28.2 ± 1.1 | 34.5 ± 0.9 | < 0.001 |
Need for postCPB inotropic support, n (%) | 2 (20%) | 2 (20%) | 1.000 |